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D
iabetic retinopathy (DR) was the leading cause
of severe visual impairment (VI) in subjects
25–64 years of age in the U.S. 30 to 40 years ago
(1,2). At that time, severe VI (best corrected
visual acuity of 20/200 or worse in the better eye) was 25
times as common in subjects with diabetes compared with
those without diabetes. VI in subjects with diabetes re-
sulted mainly from vitreous hemorrhage, tractional de-
tachment of the macula due to proliferative diabetic
retinopathy (PDR), and from macular edema involving the
foveal area due to leakage from the breakdown of the
blood-retinal barrier. Cataract and glaucoma also contrib-
uted to VI in individuals with diabetes.
Poor glycemic control was common in subjects with
diabetes at that time (3,4). This was due, in part, to the fact
that intensive appropriate insulin treatment was difﬁcult to
achieve. This was related to the technology that was
available for monitoring glucose levels (self-monitoring of
glycemic control was done by testing of spot urines; no
glycosylated hemoglobin A1c was available) and to the
way insulin was administered (no pump, treatment with
one injection per day of a long-acting insulin). There was
no deﬁnitive evidence that achieving good glycemic con-
trol would actually result in less DR; thus, there was a lack
of consensus on optimal glucose levels among physicians
caring for individuals with diabetes. Some clinicians be-
lieved that high blood glucose was less likely to result in
the development of severe DR in subjects with type 2
diabetes than in those with type 1 diabetes (5). Blood
pressure was also poorly controlled in individuals with
diabetes at that time (3,4).
In 1972, the efﬁcacy of photocoagulation had not yet
been demonstrated to prevent visual loss due to PDR or
macular edema. Vitrectomy, a surgical intervention to
restore vision in eyes with vitreous hemorrhage or trac-
tional detachments of the macula, was in its developmen-
tal stages.
The purpose of this article is to provide a historical
epidemiological perspective showing the relation of
changes in the management of diabetes and its retinal and
visual complications to the changes in the incidence and
progression of DR and VI over the past 30 years.
Evidence of a relationship of hyperglycemia to DR. In
1979, the relationship between hyperglycemia and the
development of DR had not been resolved. Kelly M. West,
in his 1978 textbook, Epidemiology of Diabetes and Its
Vascular Lesions, wrote, “The extent to which the level of
hyperglycemia determines the risk of retinopathy is not at
all clear. This is the most important issue at hand and
deserves high priority in epidemiologic research” (6).
Baseline data (1980–1982) from the Wisconsin Epidemio-
logic Study of Diabetic Retinopathy (WESDR), a cohort
study of both type 1 and type 2 diabetes showed that less
than 10% of individuals with diabetes achieved levels of
glycemia (glycosylated hemoglobin A1c 7%) and blood
pressure (130/80 mmHg) considered adequate by today’s
standards (Table 1) (3,4).
Epidemiological data from the WESDR and other cohort
studies showed that glycemic control was strongly related
to the incidence and progression of DR and that achieving
glycemic control was beneﬁcial at any time during the
course of diabetes and at any level of severity of DR prior
to the onset of PDR (7). There was no threshold level
above normal at which the lowering of glycosylated hemo-
globin levels was not associated with the lowering of risk of
incidence or progression of DR. Moreover, for a given level of
glycemia, the risk of retinopathy progressing or developing
into PDR or clinically signiﬁcant macular edema (CSME)
(the thickening of the retina involving the fovea or a certain
area threatening the fovea) was similar for both individuals
with type 1 and type 2 diabetes. This provided evidence that
glycemic control and not the type of diabetes was important
in determining risk of progression of DR.
Two large randomized therapeutic trials of metabolic
control, the Diabetes Control and Complications Trial
(DCCT) and the UK Prospective Diabetes Study (UKPDS)
(for type 1 and type 2 diabetes, respectively), provided
evidence of the efﬁcacy of intensive glycemic control (8,9).
DCCT showed an approximate 76% reduction in the pro-
gression of retinopathy in the primary prevention cohort
(subjects without DR at baseline) and a 54% reduction in
the progression of DR in the secondary prevention cohort
(subjects with mild to moderate nonproliferative diabetic
retinopathy [NPDR] at baseline) in the intensive therapy
group compared with the conventional therapy group after
ﬁve years of follow-up. DCCT data suggested that if
intensive therapy for the 120,000 subjects with type 1
diabetes in the U.S. who met DCCT criteria could maintain
a hemoglobin A1c level of 7.2% for life, 920,000 years of
sight would be gained (10). The long-term beneﬁts of
intensive treatment went well beyond its implementation
and led investigators to suggest that “intensive treatment
should be started as soon as is safely possible after the
onset of type 1 diabetes and maintained thereafter, aiming
for a practicable target HbA1c level of 7.0% or less” (11).
However, achieving intensive glycemic control in the
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hypoglycemia in the intensive insulin treatment group
compared with the conventional group.
The UKPDS showed the efﬁcacy of intensive glycemic
control in newly diagnosed type 2 diabetic individuals (9).
There was a 21% reduction in the progression of DR and a
29% reduction in the need for laser photocoagulation in the
intensive treatment group compared with the conventional
treatment group after 12 years of follow-up. Both trials
provided a basis for the American Diabetes Association
(ADA) guidelines of a target level of glycosylated hemo-
globin of 7.0% for individuals with diabetes.
Evidence of a relationship of hypertension to DR.
Randomized clinical trial data have shown the efﬁcacy of
the tight control of blood pressure in reducing the progres-
sion of DR in subjects with type 2 diabetes (12,13). In the
UKPDS, tight blood pressure control (deﬁned as achieving
blood pressure values 150/85 mmHg) in subjects with
type 2 diabetes resulted in a 34% reduction in the progres-
sion of DR and a 47% reduction in the decrease in visual
acuity of three lines or more over 71⁄2 years of follow-up
compared with conventional control (deﬁned as blood
pressure values 180/105 mmHg) (12). The reduction in
the loss of vision was due mainly to a 42% reduction in the
incidence of macular edema. In the UKPDS, the effects of
blood pressure control were independent of those attribut-
able to glycemic control. In the DIabetic REtinopathy Can-
desartan Trials (DIRECT), candesartan was associated with
a statistically insigniﬁcant reduction in the progression of DR
over a 41⁄2 year period in subjects with type 2 diabetes who
were normotensive or had controlled hypertension, as com-
pared with those randomized to a placebo (14).
Three randomized controlled clinical trials, the
EURODIAB (Epidemiology and Prevention of Diabetes
project) Controlled Trial of Lisinopril in Insulin-Dependent
Diabetes (EUCLID), the Renin-Angiotensin System Study
(RASS), and the DIRECT Prevent-1, have shown that
either ACE inhibition (ACE-I) or angiotensin receptor
blocker (ARB) reduction was associated with the reduc-
tion in the progression of DR in normotensive type 1
diabetic subjects with no or very mild DR (15–17). In each
of these trials, the effect was independent of blood pres-
sure level. It remains uncertain and speculative whether
there are pleiotropic drug effects of renin-angiotensin
blockade such that improvement in endothelial function
and reduction in oxidative stress and inﬂammation, rather
than a lowering of blood pressure, account for the efﬁcacy
of these drugs in type 1 diabetic subjects. The data, when
taken together for both types of diabetes, suggest that the
greatest efﬁcacy of ARBs and ACE-Is in decreasing DR is in
reducing blood pressure in subjects in whom it is poorly
controlled and in normotensive subjects in whom DR is
absent or minimally present. These ﬁndings have led to the
current American Heart Association guidelines of a target
goal for blood pressure of 130/80 mmHg or below the
90th percentile for age, sex, and height, whichever is
lower, for individuals with diabetes.
Fenoﬁbrate, a peroxisome proliferator–activated recep-
tor- agonist, was shown in the Fenoﬁbrate Intervention
and Event Lowering in Diabetes (FIELD) study to reduce
the incidence of laser treatment for CSME by 31% and for
PDR by 30% in subjects with type 2 diabetes (18). In a
smaller substudy in which retinopathy severity was deter-
mined by grading fundus photographs, fenoﬁbrate treat-
ment was associated with a decrease in the progression of
retinopathy. To date, no deﬁnitive clinical trials have shown
that lowering serum total or LDL cholesterol using statins
reduces the incidence and progression of DR. The Action to
Control Cardiovascular Risk in Diabetes (ACCORD) trial
may provide further insight regarding intensive control of
lipids in reducing the incidence and progression of retinop-
athy in people with type 2 diabetes (19).
Epidemiological evidence of changes in management
practices of individuals with diabetes
Controlling blood glucose. Changes in the monitoring
and management of glycemia have resulted in the lowering
of glycosylated hemoglobin over the past 30 years in some
individuals with type 1 diabetes. For example, in subjects
with type 1 diabetes in the WESDR, dramatic changes have
occurred in how glycemic control is monitored (from
testing urine to home blood glucose monitoring) and
taking insulin three or more times per day (Table 2).
This has been associated with an absolute decrease of
3.5% in the mean glycosylated hemoglobin A1c (from 10.1%
in 1980–1982 to 7.6% in 2005–2007) (Table 2). At the Steno
Diabetes Center in Denmark, individuals diagnosed more
recently with type 1 diabetes (1979–1984) were found to
TABLE 1
Characteristics of the Wisconsin Epidemiologic Study of Diabetic Retinopathy cohort in 1980–1982
Characteristic
Type 1 diabetic
subjects
Type 2 diabetic
subjects
All 15 years All 15 years
Mean glycosylated hemoglobin A1c (%) 10.1 10.0 8.9 9.3
% with glycosylated A1c 7.0% 2.7 2.2 15.2 6.1
Prevalence of hypertension (systolic BP 130 and/or diastolic BP 80 mmHg and/or
history of hypertension using antihypertensive medications) (%) 56.4 72.3 87.1 87.5
% on antihypertensive medications with controlled BP 130/80 mmHg 1.4 2.8 5.1 5.7
Prevalence of DR (%) 71.8 97.5 49.7 77.9
Prevalence of PDR (%) 22.8 48.5 5.7 14.5
Prevalence of clinically signiﬁcant macular edema (%) 5.9 11.1 5.2 15.6
% of right eyes with PDR treated with PRP 53.9 55.6 38.9 46.9
% of right eyes with clinically signiﬁcant macular edema treated with focal/grid
photocoagulation 31.7 32.0 29.3 23.2
Prevalence of visual impairment (%)* 8.0 16.4 11.7 23.8
Prevalence of severe visual impairment (%)* 3.2 7.9 1.6 4.8
*Visual impairment deﬁned as best corrected visual acuity of 20/40 or worse in the better eye; severe visual impairment as best corrected
visual acuity of 20/200 or worse in the better eye. BP, blood pressure; PRP, panretinal photocoagulation.
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than those diagnosed in 1965–1969 (20).
Data from the WESDR and the Steno Diabetes Center
are from predominantly white middle-class cohorts who
are more likely to have access to care than uninsured or
economically disadvantaged individuals. Preliminary data
from the Chicago Childhood Diabetes Registry Family
Study showed that in participants with type 1 diabetes
seen between September 2004 and April 2009, the mean
glycosylated hemoglobin A1c was 9.5%; 70% had a glyco-
sylated hemoglobin A1c level of more than 8%; and only
62% were taking three or more insulin injections per day or
using an insulin pump. These data suggest that similar
improvements in glycemic control in economically disad-
vantaged individuals with type 1 diabetes as compared to
middle class type 1 patients are not being achieved (R.
Lipton, personal communication). Thus, caution must be
taken in assuming that improvements in achieving inten-
sive glycemic control reported in the Wisconsin and
Danish studies are also occurring in those with limited
access to care.
Data from the National Health and Nutrition Survey
(NHANES) has shown that there have been changes by
clinicians in the management of glycemia in people with
type 2 diabetes after publication of the UKPDS results in
1997 (21–23). There was increased use of more than one
oral hypoglycemic agent (metformin and thiazolidinedione
in 1999–2004) from the predominant use of one type of
oral agent (sulfonylureas in 1988–1994) (21,22). This was
accompanied by a drop in the mean glycosylated hemo-
globin A1c levels from 7.8 to 7.2%, attaining glycosylated
hemoglobin levels of 7.0% in 41% and 58% of those with
type 2 diabetes in the U.S. population examined in the
NHANES in 1999–2000 and 2005–2006, respectively (24).
This improvement in glycemic control among medication-
treated individuals with type 2 diabetes was found in
non-Hispanic whites but not in non-Hispanic blacks or
Mexican Americans (21).
To our knowledge, there are no long-term longitudinal
epidemiologic data showing similar changes in manage-
ment and glycemic control in subjects with type 2 diabetes
in developing countries, where the prevalence of type 2
diabetes is expected to increase by 21⁄2 times by the year
2030.
Controlling blood pressure. Some long-term epidemio-
logical studies have also shown changes in the manage-
ment of hypertension and resulting changes in blood
pressure over time. For example, in the Steno Diabetes
Center study, the time from diagnosis of type 1 diabetes to
initiation of antihypertensive treatment was shortened, the
use of ACE-I became more frequent, and the mean arterial
blood pressure decreased with each more recent period of
diagnosis of type 1 diabetes (from 1965–1969 through 1979–
1984) (20). In the WESDR, when using the current ADA
guidelines of a target blood pressure of 130/80 mmHg for
diabetic individuals with hypertension, the percentage of
type 1 diabetic participants with blood pressure reaching this
goal improved from 1.4% at the 1980–1982 examination to
22.4% at the 2005–2007 examination (Table 2). At the last
examination, 56.8% of those with type 1 diabetes with hyper-
tension were taking ACE-I or ARB.
Blood pressure control appears to be improving in sub-
jects with type 2 diabetes. In the NHANES examination from
1999–2000 to 2005–2006, the frequency of controlled hyper-
tension (130/80 mmHg) increased from 16 to 29% (24).
Changes in eye care. In the WESDR, only 67% of
subjects with Diabetic Retinopathy Study (DRS) high-risk
characteristics for severe visual loss or CSME had been
examined by an ophthalmologist within two years prior to
the study examination. Lack of symptoms, not being told
they needed such examinations, and the cost of the
examinations were the main reasons given by the subjects
for not being seen by an ophthalmologist. Guidelines for
whom, when, and how often to be seen were developed
based on these and other observations, which showed
many diabetic subjects with a higher risk of vision loss were
not receiving timely dilated eye examinations. Educating
diabetic patients and their physicians about the need for
timely eye examinations led the National Eye Institute to
initiate the National Eye Health Education Program in the
early 1990s. That program, along with the World Health
Organization’s Saint Vincent Declaration, led to the initiation
of screening programs in the U.K. and other European
countries for the timely detection and treatment of patients
with PDR who have a higher risk of visual loss and CSME. In
areas where active screening for DR has been implemented,
lower incidence of severe VI has been found (25).
TABLE 2
Changes in management and measurement of glycemia and blood pressure in subjects with type 1 diabetes in the Wisconsin
Epidemiologic Study of Diabetic Retinopathy, 1980–2007
Baseline 4 year 10 year 14 year 25 year
1980–1982 1984–1986 1990–1992 1994–1996 2005–2007
Urine dipstick testing for glucose (%) 71.8 41.6 13.5 7.9 N/A
Self blood glucose monitoring (%)* N/A 72.3 80.2 85.8 90.7
Average number of blood glucose monitorings per day* N/A 1.2 1.9 2.5 4.6
3 insulin injections per day or pump use (%) 3.6 11.5 24.3 38.3 84.5
Pump use (%) 1.0 1.4 1.4 3.4 35.5
Mean glycosylated hemoglobin A1c (%) 10.1 9.4 9.3 8.9 7.6
% controlled glycosylated hemoglobin A1c 7.0% 3.7 6.7 6.3 7.4 33.1
% taking ACE-Is or ARBs N/A 0.9 10.9 19.9 56.8
Mean arterial BP (mmHg controlling for age) 100.2 94.7 93.3 92.9 92.2
% BP controlled 130/80 mmHg on antihypertensive
medications 1.4 5.4 10.2 16.7 22.4
% of persons with 5 years of diabetes seen by an
ophthalmologist within 1 year of study exam 56 54 67 74 67
*Question not asked at baseline exam. BP, blood pressure; N/A, not applicable.
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controlled clinical trials, the DRS and the Early Treatment
Diabetic Retinopathy Study (ETDRS), demonstrated the
efﬁcacy of photocoagulation in preventing visual loss in
subjects with PDR and CSME, respectively (26,27). In the
WESDR from 1980 through 1982, a high proportion of eyes
with PDR and CSME in subjects with diabetes had not
received panretinal photocoagulation or focal and/or grid
photocoagulation treatment (Table 1) (28). Over time,
there has been an increase in the proportion of eyes with
PDR and CSME that have had panretinal and macular
focal/grid treatment, respectively (Fig. 1).
Epidemiological evidence of changes in incidence and
prevalence of PDR, CSME, and VI. In 1980–1982, PDR,
CSME, and severe VI were frequent in subjects with 15 or
more years of diabetes (Table 1). There is evidence that
the prevalence and incidence of DR may be decreasing in
subjects more recently diagnosed with type 1 diabetes.
Hovind et al. (20) ﬁrst showed a declining incidence of
PDR and macular edema in a study of 600 patients with
type 1 diabetes diagnosed between 1965 and 1984 in
Denmark. The cumulative incidence of PDR and macular
edema after 20 years of diabetes declined from 31 to 19%
in those diagnosed from 1965 to 1969 to 13 and 7%,
respectively, in those diagnosed from 1979 to 1984. There
was also signiﬁcant improvement in visual acuity and less
severe VI prevalence in those diagnosed with type 1
diabetes more recently than those diagnosed in earlier
periods. These changes were attributed to improved gly-
cemic control, more aggressive treatment of blood pres-
sure sooner after diagnosis of diabetes, and reduced
smoking rates in the more recently diagnosed type 1
diabetic group than in previous years.
The Linko ¨ping Diabetes Complications Study examined
the incidence of laser-treated severe retinopathy (both
PDR and CSME) after 20 years of diabetes in an unselected
population with type 1 diabetes diagnosed from 1961 to
1984 (29,30). The authors reported a statistically signiﬁ-
cant decline in the cumulative proportion with severe
laser-treated DR after 25 years of type 1 diabetes from 47% in
subjects diagnosed in 1961–1965 to 24% in subjects diagnosed
in 1971–1975. There was no signiﬁcant decline in the cumu-
lative proportion with NPDR in the same time period in this
study. The Pittsburgh Epidemiology of Diabetic Complica-
tions Study did not show a signiﬁcant decrease in PDR with
more recent year of type 1 diabetes diagnosis over a 25-year
period of follow-up (31).
In the WESDR, the annualized estimates for the progres-
sion of DR and the incidence of PDR, CSME, and VI were
higher in the ﬁrst 12 years of the study (1980–1992) than in
the latest 13 years of the study (1994–2007) (Fig. 2)
(32–35). There was also evidence in the WESDR of lower
prevalence of PDR (4% lower per more recent period) and
VI (9% lower per more recent period) but not of macular
edema in those diagnosed with type 1 diabetes more
recently than those diagnosed in the past (Figs. 3 and 4).
The relationships remained when adjusting for hyperten-
sion and glycosylated hemoglobin levels over time. The
WESDR ﬁndings are consistent with a decline in the
prevalence of diabetic nephropathy and better survival in
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FIG. 1. Prevalence of right eyes with PDR treated with panretinal photocoagulation (PRP) (A) and CSME treated with focal and/or grid
photocoagulation (B) in WESDR subjects with type 1 diabetes, and PDR treated with PRP (C) and CSME treated with focal and/or grid
photocoagulation (D) in WESDR subjects with type 2 diabetes.
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periods. In the Wisconsin Diabetes Registry Study (36),
among an incipient cohort of individuals diagnosed with
type 1 diabetes 7 to 12 years after the WESDR, the
prevalence of PDR at 15 or 20 years of diabetes was
signiﬁcantly lower than in the WESDR.
It is possible that the estimates of a reduction in the
incidence of DR and other complications associated with
the improvement in glycemic control reported in the
WESDR and Hovind studies may actually underestimate
the effect in those currently being diagnosed with type 1
diabetes (20,32–35). The DCCT ﬁndings showed that inten-
sive therapy was more beneﬁcial when started earlier in
the course of type 1 diabetes, prior to the onset of DR.
Four and ten years of additional follow-up of the DCCT/
Epidemiology of Diabetes Interventions and Complica-
tions (EDIC) cohort after the study medication regimen
was discontinued revealed that despite convergence of
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FIG. 2. Estimated annual incidence of PDR, progression of DR, incidence of CSME, and incidence of VI in type 1 diabetic subjects in two
examination periods (1980–1992 and 1994–2007) in the WESDR.
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FIG. 3. Prevalence of PDR by diabetes duration and period of diagnosis (1922–1959, 1960–1969, 1970–1974, and 1975–1980) in the WESDR. Figure
adapted from Klein et al. (32).
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ventional groups, the protective effect of glycemic control
was maintained in the intensive group, an effect labeled
metabolic memory (11). A comparison of the conventional
with the intensive DCCT/EDIC cohort and a population-
based cohort showed that after 30 years of diabetes, the
cumulative incidence of PDR was 50% in the DCCT con-
ventional treatment group, 47% in the population-based
cohort, and 21% in the DCCT intensive group (37). These
data suggest that if intensive glycemic control can be
achieved and maintained in subjects with newly diagnosed
type 1 diabetes, a further decrease in the incidence of DR
and visual loss is likely in the future.
There is, however, less certainty as to whether there has
been a similar decline in the prevalence and incidence of
DR in subjects with type 2 diabetes. In WESDR partici-
pants 40 years of age or older in 1980–1982 with type 2
diabetes, the crude prevalence of any DR and visually
threatening DR was higher (50 vs. 35% and 10 vs. 3%,
respectively) than in subjects with type 2 diabetes in the
Beaver Dam Eye Study in 1988–1990, suggesting a signif-
icant drop in prevalence over the 8-year period between
the two studies (38). On the other hand, in the Blue
Mountains Eye Study in Australia, the prevalence of any
DR increased from 27% in 1992–1994 to 34% in 1997–2000.
This study found a lower prevalence of moderate to severe
DR in those examined more recently (39). Similarly, the
overall prevalence of DR in the Melbourne Visual Impair-
ment Study increased slightly from 29% in 1992 to 36% in
1997 (40,41).
Medicare data from two cohorts (1994–1999 and 2000–
2005) of individuals 65 years or older and newly diagnosed
with type 2 diabetes were compared. There was a decrease
in the cumulative incidence of DR, PDR, and macular
edema of 17, 23, and 9%, respectively (42), in the more
recently diagnosed cohort.
The duration-speciﬁc prevalence of NPDR was lower
and PDR was similar in a study comparing members of an
HMO with type 2 diabetes in 1997–1998 compared with the
WESDR cohort in 1980–1982 (43). The authors concluded
that the lower prevalence of NPDR was due to earlier
diagnosis of type 2 diabetes and more aggressive control
of blood glucose (HbA1c 7.8% vs. 10.4%) and blood pres-
sure (139/79 vs. 147/79 mmHg) in their clinic compared
with the WESDR cohort. The lack of a difference in PDR
was hypothesized to result from rapid intensiﬁcation of
glucose control in the HMO group. However, while rapid
management of hyperglycemia in poorly controlled dia-
betic individuals may be responsible for the progression of
DR in some diabetic individuals, previous clinical trials
have not shown a difference in the incidence of PDR
between intensive and conventional treatment arms of the
studies. Ascertainment differences for DR between studies
may also explain these ﬁndings (44).
To our knowledge, no recent U.S. national estimates of
the prevalence of DR and visual acuity in subjects with
type 2 diabetes have been released since the UKPDS
results were published in 1997. Comparison of data from
the 1988–1994 NHANES III with data from the 2005–2008
NHANES (not yet published) may provide useful informa-
tion regarding changes in the frequency of these ocular
complications in type 2 diabetic individuals. However,
because of signiﬁcant changes in diagnostic criteria for
deﬁning the presence of type 2 diabetes in the population
and different methods of assessing the presence of reti-
nopathy in type 2 diabetic individuals (digital vs. ﬁlm, area
of retina photographed), such comparisons may be lim-
ited. To our knowledge, no data on the ocular lesions of
diabetes or their functional visual sequelae are available
from developing countries, where the prevalence of dia-
betes is expected to increase as their populations become
more sedentary and obese.
New interventions. While the incidence of late vision-
threatening complications such as CSME and PDR has
decreased considerably as a result of intensive glycemic
and blood pressure control, and while the DRS and the
ETDRS have shown the efﬁcacy of timely intervention with
photocoagulation for those who develop these complica-
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FIG. 4. Prevalence of VI (deﬁned by best corrected visual acuity of 20/40 or worse in the better eye) by diabetes duration and period of diagnosis
(1922–1959, 1960–1969, 1970–1974, and 1975–1980) in the WESDR.
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suffer visual loss as a result of these complications still
remain. Adjunct medical approaches have been devel-
oped—some of which were shown to have no efﬁcacy in
clinical trials (e.g., aldose reductase inhibitors), while
others are still under evaluation (e.g., protein kinase C
inhibitors, intravitreal triamcinolone) (45,46).
Among all these new interventions, a phase 3 controlled
multicenter clinical trial of vascular endothelial growth
factor (VEGF) inhibitors to reduce leakage and retinal
thickness in eyes with macular edema was initiated (47).
The trial was based on a ﬁnding that increased VEGF
levels in the retina and vitreous of eyes with DR increases
retinal vessel permeability by affecting phosphorylation of
tight junction proteins. The trial showed that the anti-
VEGF agent bevacizumab with prompt or deferred (24
weeks) focal/grid laser reduced macular thickening and
improved vision at both the one and two-year follow-ups.
There were no systemic side effects, and mortality did not
increase; however, there were three cases of injection-
related endophthalmitis in the treated group. Further
evaluation of the risks and beneﬁts of anti-VEGF treatment
is needed in large phase 3 long-term randomized con-
trolled clinical trials.
Future needs. Data from the WESDR and other studies
have shown associations of hyperglycemia with the inci-
dence and progression of retinopathy and other micro-
vascular and macrovascular complications in diabetic
subjects (48). However, while intensive glycemic control is
beneﬁcial in reducing complications, it is associated with
severe hypoglycemic reactions sometimes resulting in
coma or seizures, making it difﬁcult for many type 1
diabetic individuals to adhere to an intensive insulin
treatment regimen (49). Thus, because intensive insulin
treatment is associated with signiﬁcant morbidity (e.g.,
hypoglycemia) and because glycemia is difﬁcult to control,
it is important to improve the technology to achieve more
physiologic administration of insulin. It is also important
to identify genetic and novel risk factors that can be used
to develop new approaches to prevent the incidence and
progression of DR.
Current population-based estimates of prevalence and
incidence of DR and continuing surveillance are needed to
estimate the burden of these complications as well as the
effectiveness of new interventions, e.g., use of fenoﬁbrate
and intravitreal injections of anti-VEGF agents over time.
This is especially important in a time of changing preva-
lence of complications and evolving preventive therapies.
It is also important to understand how methodological
(e.g., how the cohort was ascertained, effects of nonpar-
ticipation, inaccuracy of dating onset of type 2 diabetes,
effects of censuring due to mortality) and biological issues
(e.g., metabolic memory, rapid intensiﬁcation of glycemic
control) will affect estimates of incidence and progression
of DR in future epidemiological studies.
Summary. Data from epidemiological studies have shown
remarkable improvements in the care and management of
diabetes associated with signiﬁcant decreases in the prev-
alence and incidence of DR and VI in type 1 diabetic
individuals over the past 30 years. Limited long-term
epidemiological data are available to determine whether
similar trends exist for individuals with type 2 diabetes.
Epidemiological studies have disclosed the high incidence
of DR and its association with poor glycemic and blood
pressure control. They have also described the infre-
quency of dilated eye examinations and infrequent timely
treatment with photocoagulation in patients with late stages
of DR. New technologies to monitor glycemic control and
new drugs to treat hyperglycemia and hypertension have
proven effective in decreasing vision-threatening retinopathy.
These, coupled with the development of educational and
surveillance programs for detection and early treatment of
ocular complications, have played major roles in this de-
crease in DR and VI in subjects with type 1 diabetes and
possibly in subjects with type 2 diabetes. While this repre-
sents a public health success for those with access to health
care, it is unclear whether similar improvements in manage-
ment are occurring in the growing number of people with
type 2 diabetes in areas where access to health care is poor.
ACKNOWLEDGMENTS
This research is supported by National Institutes of Health
Grants EY03083 and EY016379 (R.K. and B.E.K.K.) and, in
part, by Research to Prevent Blindness (R.K. and B.E.K.K.,
Senior Scientiﬁc Investigator Awards), New York, New
York.
R.K. has served as a consultant to AstraZeneca, Lilly,
and Pﬁzer. No other potential conﬂicts of interest relevant
to this article were reported.
R.K. wrote the manuscript and researched the data.
B.E.K.K. reviewed and edited the manuscript and wrote
parts of the manuscript.
The authors thank Scot Moss, Kristine E. Lee, and
Chelsea Myers for contributing their statistical expertise,
and Heidi Gutt for technical assistance and editing of the
manuscript.
REFERENCES
1. National Society to Prevent Blindness. Vision Problems in the US: Data
Analysis, Deﬁnitions, Data Sources, Detailed Data Tables, Analyses,
Interpretation. New York, NY, National Society to Prevent Blindness, 1980
2. Kahn HA, Moorhead HB. Statistics on Blindness in the Model Reporting
Area, 1969–70. National Eye Institute, Washington, DC, Superintendent of
Documents, U.S. Govt. Printing Ofﬁce, 1973 (DHEW Pub. No. [NIH]
73–427)
3. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin
Epidemiologic Study of Diabetic Retinopathy. II. Prevalence and risk of
diabetic retinopathy when age at diagnosis is less than 30 years. Arch
Ophthalmol 1984;102:520–526
4. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin
Epidemiologic Study of Diabetic Retinopathy. III. Prevalence and risk of
diabetic retinopathy when age at diagnosis is 30 or more years. Arch
Ophthalmol 1984;102:527–532
5. Ingelﬁnger FJ. Debates on diabetes. N Engl J Med 1977;296:1228–1230
6. West KM. Epidemiology of Diabetes and Its Vascular Lesions. New York,
NY, Elsevier, 1978
7. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. Glycosylated hemo-
globin predicts the incidence and progression of diabetic retinopathy.
JAMA 1988;260:2864–2871
8. Diabetes Control and Complications Trial Research Group. The effect of
intensive treatment of diabetes on the development and progression of
long-term complications in insulin-dependent diabetes mellitus. N Engl
J Med 1993;329:977–986
9. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose
control with sulphonylureas or insulin compared with conventional treat-
ment and risk of complications in patients with type 2 diabetes (UKPDS
33). Lancet 1998;352:837–853
10. Diabetes Control and Complications Trial Research Group. Lifetime ben-
eﬁts and costs of intensive therapy as practiced in the Diabetes Control
and Complications Trial. JAMA 1996;276:1409–1415
11. Writing Team for the Diabetes Control and Complications Trial/Epidemi-
ology of Diabetes Interventions and Complications Research Group. Effect
of intensive therapy on the microvascular complications of type 1 diabetes
mellitus. JAMA 2002;287:2563–2569
12. UK Prospective Diabetes Study Group. Tight blood pressure control and
risk of macrovascular and microvascular complications in type 2 diabetes:
UKPDS 38. BMJ 1998;317:703–713
R. KLEIN AND B.E.K. KLEIN
diabetes.diabetesjournals.org DIABETES, VOL. 59, AUGUST 2010 185913. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood
pressure control in normotensive type 2 diabetic patients on albuminuria,
retinopathy and strokes. Kidney Int 2002;61:1086–1097
14. Sjølie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH, Bilous R,
Chaturvedi N, DIRECT Programme Study Group. Effect of candesartan on
progression and regression of retinopathy in type 2 diabetes (DIRECT-
Protect 2): a randomised placebo-controlled trial. Lancet 2008;372:1385–
1393
15. Chaturvedi N, Sjolie AK, Stephenson JM, Abrahamian H, Keipes M,
Castellarin A, Rogulja-Pepeonik Z, Fuller JH. Effect of lisinopril on
progression of retinopathy in normotensive people with type 1 diabetes.
The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in
Insulin-Dependent Diabetes Mellitus. Lancet 1998;351:28–31
16. Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH, Bilous R,
Sjølie AK, DIRECT Programme Study Group. Effect of candesartan on
prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of
retinopathy in type 1 diabetes: randomised, placebo-controlled trials.
Lancet 2008;372:1394–1402
17. Mauer M, Zinman B, Gardiner R, Suissa S, Sinaiko A, Strand T, Drummond
K, Donnelly S, Goodyer P, Gubler MC, Klein R. Renal and retinal effects of
enalapril and losartan in type 1 diabetes. N Engl J Med 2009;361:40–51
18. Keech AC, Mitchell P, Summanen PA, O’Day J, Davis TM, Mofﬁtt MS,
Taskinen MR, Simes RJ, Tse D, Williamson E, Merriﬁeld A, Laatikainen LT,
d’Emden MC, Crimet DC, O’Connell RL, Colman PG, FIELD study inves-
tigators. Effect of fenoﬁbrate on the need for laser treatment for diabetic
retinopathy (FIELD study): a randomised controlled trial. Lancet 2007;370:
1687–1697
19. Ginsberg HN, Bonds DE, Lovato LC, Crouse JR, Elam MB, Linz PE,
O’Connor PJ, Leiter LA, Weiss D, Lipkin E, Fleg JL, ACCORD Study Group.
Evolution of the lipid trial protocol of the Action to Control Cardiovascular
Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007;99:56i–67i
20. Hovind P, Tarnow L, Rossing K, Rossing P, Eising S, Larsen N, Binder C,
Parving HH. Decreasing incidence of severe diabetic microangiopathy in
type 1 diabetes. Diabetes Care 2003;26:1258–1264
21. Suh DC, Choi IS, Plauschinat C, Kwon J, Baron M. Impact of comorbid
conditions and race/ethnicity on glycemic control among the US popula-
tion with type 2 diabetes, 1988–1994 to 1999–2004. J Diabetes Complica-
tions. 26 August 2009 [Epub ahead of print]
22. Ong KL, Cheung BM, Wong LY, Wat NM, Tan KC, Lam KS. Prevalence,
treatment, and control of diagnosed diabetes in the U.S. National Health
and Nutrition Examination Survey 1999–2004. Ann Epidemiol 2008;18:222–
229
23. Cheung BM, Ong KL, Cherny SS, Sham PC, Tso AW, Lam KS. Diabetes
prevalence and therapeutic target achievement in the United States, 1999
to 2006. Am J Med 2009;122:443–453
24. Mann DM, Woodward M, Ye F, Krousel-Wood M, Muntner P. Trends in
medication use among US adults with diabetes mellitus: glycemic control
at the expense of controlling cardiovascular risk factors. Arch Intern Med
2009;169:1718–1720
25. Ba ¨cklund LB, Algvere PV, Rosenqvist U. New blindness in diabetes
reduced by more than one-third in Stockholm County. Diabet Med
1997;14:732–740
26. Diabetic Retinopathy Study Research Group. Photocoagulation treatment
of proliferative diabetic retinopathy. Clinical application of Diabetic Reti-
nopathy Study (DRS) ﬁndings, DRS report number 8. Ophthalmology
1981;88:583–600
27. Early Treatment Diabetic Retinopathy Study Research Group. Photocoag-
ulation for diabetic macular edema. Early Treatment Diabetic Retinopathy
Study report number 1. Arch Ophthalmol 1985;103:1796–1806
28. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin
Epidemiologic Study of Diabetic Retinopathy. VI. Retinal photocoagula-
tion. Ophthalmology 1987;94:747–753
29. Bojestig M, Arnqvist HJ, Karlberg BE, Ludvigsson J. Unchanged incidence
of severe retinopathy in a population of type 1 diabetic patients with
marked reduction of nephropathy. Diabet Med 1998;15:863–869
30. Nordwall M, Bojestig M, Arnqvist HJ, Ludvigsson J, Linko ¨ping Diabetes
Complications Study. Declining incidence of severe retinopathy and per-
sisting decrease of nephropathy in an unselected population of type 1
diabetes: the Linko ¨ping Diabetes Complications Study. Diabetologia 2004;
47:1266–1272
31. Pambianco G, Costacou T, Ellis D, Becker DJ, Klein R, Orchard TJ. The
30-year natural history of type 1 diabetes complications: the Pittsburgh
Epidemiology of Diabetes Complications Study experience. Diabetes 2006;
55:1463–1469
32. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin
Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-ﬁve-year
progression of retinopathy in persons with type 1 diabetes. Ophthalmology
2008;115:1859–1868
33. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin
Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-ﬁve-year
incidence of macular edema in persons with type 1 diabetes. Ophthalmol-
ogy 2009;116:497–503
34. Klein R, Lee KE, Gangnon RE, Klein BE. The 25-year incidence of visual
impairment in type 1 diabetes mellitus: the Wisconsin Epidemiologic Study
of Diabetic Retinopathy. Ophthalmology 2010;117:63–70
35. Klein R, Lee KE, Knudtson MD, Gangnon RE, Klein BE. Changes in visual
impairment prevalence by period of diagnosis of diabetes: the Wisconsin
Epidemiologic Study of Diabetic Retinopathy. Ophthalmology 2009;116:
1937–1942
36. Lecaire T, Palta M, Zhang H, Allen C, Klein R, D’Alessio D. Lower-than-
expected prevalence and severity of retinopathy in an incident cohort
followed during the ﬁrst 4–14 years of type 1 diabetes: the Wisconsin
Diabetes Registry Study. Am J Epidemiol 2006;164:143–150
37. Diabetes Control and Complications Trial/Epidemiology of Diabetes Inter-
ventions and Complications (DCCT/EDIC) Research Group, Nathan DM,
Zinman B, Cleary PA, Backlund JY, Genuth S, Miller R, Orchard TJ.
Modern-day clinical course of type 1 diabetes mellitus after 30 years’
duration: the diabetes control and complications trial/epidemiology of
diabetes interventions and complications and Pittsburgh epidemiology of
diabetes complications experience (1983–2005). Arch Intern Med 2009;169:
1307–1316
38. Kempen JH, O’Colmain BJ, Leske MC, Haffner SM, Klein R, Moss SE,
Taylor HR, Hamman RF, Eye Diseases Prevalence Research Group. The
prevalence of diabetic retinopathy among adults in the United States. Arch
Ophthalmol 2004;122:552–563
39. Cugati S, Kiﬂey A, Mitchell P, Wang JJ. Temporal trends in the age-speciﬁc
prevalence of diabetes and diabetic retinopathy in older persons: popula-
tion-based survey ﬁndings. Diabetes Res Clin Pract 2006;74:301–308
40. McKay R, McCarty CA, Taylor HR. Diabetic retinopathy in Victoria,
Australia: the Visual Impairment Project. Br J Ophthalmol 2000;84:865–870
41. McCarty DJ, Fu CL, Harper CA, Taylor HR, McCarty CA. Five-year
incidence of diabetic retinopathy in the Melbourne Visual Impairment
Project. Clin Experiment Ophthalmol 2003;31:397–402
42. Sloan FA, Belsky D, Ruiz D Jr, Lee P. Changes in incidence of diabetes
mellitus-related eye disease among US elderly persons, 1994–2005. Arch
Ophthalmol 2008;126:1548–1553
43. Brown JB, Pedula KL, Summers KH. Diabetic retinopathy: contemporary
prevalence in a well-controlled population. Diabetes Care 2003;26:2637–
2642
44. Klein R. Has the frequency of proliferative diabetic retinopathy declined in
the US? Diabetes Care 2003;26:2691–2692
45. Simo ´ R, Herna ´ndez C. Advances in the medical treatment of diabetic
retinopathy. Diabetes Care 2009;32:1556–1562
46. Nicholson BP, Schachat AP. A review of clinical trials of anti-VEGF agents
for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2010;248:915–
930
47. Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP,
Beck RW, Bressler NM, Bressler SB, Edwards AR, Ferris FL 3rd, Friedman
SM, Glassman AR, Miller KM, Scott IU, Stockdale CR, Sun JK. Randomized
trial evaluating ranibizumab plus prompt or deferred laser or triamcino-
lone plus prompt laser for diabetic macular edema. Ophthalmology
2010;117:1064–1077
48. Klein R, Klein BE Harris MI, Cowie CC, Stern MP, Boyko EJ, Reiber GE,
Bennett PH. (Eds.). Vision Disorders in Diabetes, 2nd edition. Bethesda,
MD, National Diabetes Data Group, 2009 (NIH Publication No. 95–1468),
p. 293–338
49. Diabetes Control and Complications Trial Research Group. Hypoglycemia
in the Diabetes Control and Complications Trial. Diabetes 1997;46:271–286
CHANGING VISION IN DIABETES
1860 DIABETES, VOL. 59, AUGUST 2010 diabetes.diabetesjournals.org